Healthcare Industry News: Medarex
News Release - April 11, 2006
Biolex Therapeutics Announces Expansion of Medarex CollaborationAgreement Expanded to Include Three Medarex Monoclonal Antibodies
PITTSBORO, N.C., April 11 (HSMN NewsFeed) -- Biolex Therapeutics today announced the expansion of its collaboration with Medarex, Inc., an antibody therapeutics company. The collaboration was initially formed in February of 2005 to create a commercial line for an undisclosed Medarex monoclonal antibody using the Biolex LEX System(SM). As a result of the successful achievement of the scientific goals for the first monoclonal antibody, the collaboration has been expanded to include commercial line creation for two additional Medarex antibodies.
Biolex will conduct commercial line creation projects using its proprietary LEX System for each of these two additional Medarex antibodies. At Medarex's option, it may elect to engage Biolex to scale-up and manufacture these proteins following the commercial line creation phase.
About Biolex Therapeutics
Biolex Therapeutics applies its unique drug development capabilities and expertise to commercialize complex proteins and monoclonal antibodies. Biolex' patented LEX System uses Lemna as a transgenic host in its GMP biopharmaceutical manufacturing facility to produce therapeutic proteins to support its own development programs as well as the programs of its strategic partners. The company is advancing a proprietary pipeline of product candidates, including its lead program Locteron(TM) for the treatment of hepatitis C under joint development with OctoPlus. Biolex has a multi-protein strategic alliance with Centocor and collaborations with other pharmaceutical/biotech companies including Medarex. Biolex is a venture- capital backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex' web site at www.biolex.com.
Source: Biolex Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.